MX2017006268A - Administracion intranasal. - Google Patents

Administracion intranasal.

Info

Publication number
MX2017006268A
MX2017006268A MX2017006268A MX2017006268A MX2017006268A MX 2017006268 A MX2017006268 A MX 2017006268A MX 2017006268 A MX2017006268 A MX 2017006268A MX 2017006268 A MX2017006268 A MX 2017006268A MX 2017006268 A MX2017006268 A MX 2017006268A
Authority
MX
Mexico
Prior art keywords
nosepiece
oxytocin
antagonists
providing
intranasal administration
Prior art date
Application number
MX2017006268A
Other languages
English (en)
Inventor
Gisle Djupesland Per
A Mahmoud Ramy
David Sheldrake Colin
A Andreassen Ole
T Westlye Lars
S Quintana Daniel
T Smerud Knut
Original Assignee
Optinose As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optinose As filed Critical Optinose As
Publication of MX2017006268A publication Critical patent/MX2017006268A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0098—Activated by exhalation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M29/00—Dilators with or without means for introducing media, e.g. remedies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un dispositivo de suministro para y un método de modulación de una condición relacionada con la cognición y/o comportamiento social en un sujeto humano mediante el uso de oxitocina, agonistas no peptídicos de la misma y/o antagonistas de la misma, que comprende: proporcionar un aplicador nasal a una primera cavidad nasal del sujeto; y proporcionar una unidad de suministro para administrar menos de 24IU de oxitocina, agonistas no peptídicos de la misma y/o antagonistas de la misma a través del aplicador nasal a una región superior posterior de la válvula nasal la cual es inervada por el nervio trigémino.
MX2017006268A 2014-11-19 2015-11-19 Administracion intranasal. MX2017006268A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081742P 2014-11-19 2014-11-19
PCT/EP2015/077162 WO2016079267A1 (en) 2014-11-19 2015-11-19 Intranasal administration

Publications (1)

Publication Number Publication Date
MX2017006268A true MX2017006268A (es) 2017-08-14

Family

ID=54695714

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006268A MX2017006268A (es) 2014-11-19 2015-11-19 Administracion intranasal.
MX2017006265A MX2017006265A (es) 2014-11-19 2015-11-19 Administracion intranasal.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017006265A MX2017006265A (es) 2014-11-19 2015-11-19 Administracion intranasal.

Country Status (18)

Country Link
US (5) US11052204B2 (es)
EP (3) EP3220989B1 (es)
JP (2) JP6990583B2 (es)
KR (2) KR20170086599A (es)
CN (3) CN107106792B (es)
AU (2) AU2015348301B2 (es)
BR (2) BR112017010522B1 (es)
CA (2) CA2966802C (es)
DK (2) DK3220988T3 (es)
ES (3) ES2906984T3 (es)
HK (2) HK1244729A1 (es)
IL (2) IL251935A0 (es)
MX (2) MX2017006268A (es)
MY (1) MY188242A (es)
RU (2) RU2017114950A (es)
SG (2) SG11201703792XA (es)
WO (2) WO2016079267A1 (es)
ZA (1) ZA201704149B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311570D0 (en) 2003-05-20 2003-06-25 Optinose As Delivery device and method
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
GB0420513D0 (en) 2004-09-15 2004-10-20 Optinose As Powder delivery devices
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
GB0604444D0 (en) * 2006-03-06 2006-04-12 Optinose As Nasal devices
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
GB0623731D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery device
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
GB2448193A (en) 2007-04-05 2008-10-08 Optinose As Nasal delivery device
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
MX352029B (es) 2012-02-24 2017-11-07 Optinose As Dispositivos de suministro nasal.
USD761951S1 (en) 2013-05-23 2016-07-19 Optinose As Nosepiece unit
CN107106792B (zh) 2014-11-19 2020-08-18 奥普蒂诺斯公司 经鼻给药
US10368502B2 (en) 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
WO2019195944A1 (en) 2018-04-12 2019-10-17 Fortitude Corp. Intranasal drug delivery device, system, and process
KR102148613B1 (ko) * 2019-01-28 2020-10-14 닉스 주식회사 이산화탄소를 이용한 수면 유도시스템
CN110188836B (zh) * 2019-06-21 2021-06-11 西安交通大学 一种基于变分自编码器的脑功能网络分类方法
US20220313895A1 (en) * 2019-08-14 2022-10-06 Gsk Consumer Healthcare Sarl Bi-material nozzle for nasal washes
AU2020335930A1 (en) 2019-08-29 2022-03-24 Maskbegone Llc Oxytocin compositions for treatment of tinnitus
CN114306207A (zh) * 2021-12-30 2022-04-12 电子科技大学 一种以棒棒糖为载体的口腔给药方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US605436A (en) 1898-06-07 Inhaler
US642748A (en) 1899-02-23 1900-02-06 Arthur Manners Inhaler.
US658436A (en) 1900-05-28 1900-09-25 Hans Hennerich Groth Insufflator.
US746749A (en) 1903-03-18 1903-12-15 George E Seidel Nasal medicator.
US794641A (en) 1905-03-06 1905-07-11 Alfred H Ramey Inhaler.
US902832A (en) 1907-09-20 1908-11-03 Edward F Philbrook Inhaler.
ES2145421T3 (es) 1995-01-23 2000-07-01 Direct Haler A S Inhalador.
US5901703A (en) 1995-02-06 1999-05-11 Unisia Jecs Corporation Medicine administering device for nasal cavities
JP3320288B2 (ja) * 1995-11-15 2002-09-03 株式会社ユニシアジェックス 鼻腔用投薬器
US5797392C1 (en) 1996-01-22 2001-01-09 Direct Haler As Inhaler
EP0986413B1 (en) 1997-05-27 2004-09-01 Direct-Haler A/S Inhaler for powdered medicaments
GB9719775D0 (en) * 1997-09-18 1997-11-19 Glaxo Group Ltd Device
FR2771296B1 (fr) 1997-11-25 2000-03-10 Sofab Embout nasal avec fermeture d'extremite
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
WO2000051672A1 (en) 1999-03-03 2000-09-08 Optinose As Nasal delivery device
US6894026B1 (en) 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
GB0015309D0 (en) 2000-06-21 2000-08-16 Djupesland Per G Apparatus
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
GB0215270D0 (en) 2002-07-02 2002-08-14 Optinose As Nasal devices
GB0215904D0 (en) 2002-07-09 2002-08-21 Team Holdings Uk Ltd Drug delivery system and method
GB0300008D0 (en) 2003-01-02 2003-02-05 Optinose As Delivery devices
GB2400565B (en) 2003-04-17 2005-03-02 Bespak Plc Nasal drug delivery
GB0311570D0 (en) 2003-05-20 2003-06-25 Optinose As Delivery device and method
GB0319119D0 (en) 2003-08-14 2003-09-17 Optinose As Delivery devices
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
GB0405477D0 (en) * 2004-03-11 2004-04-21 Glaxo Group Ltd A fluid dispensing device
USD530815S1 (en) 2004-03-19 2006-10-24 Optinose As Nasal delivery device
GB0420513D0 (en) 2004-09-15 2004-10-20 Optinose As Powder delivery devices
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
JP2009506076A (ja) 2005-08-26 2009-02-12 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 三叉神経疼痛のための薬物送達のための治療手順
JP4765526B2 (ja) 2005-10-04 2011-09-07 オムロンヘルスケア株式会社 吸入器および吸入器用マウスピース
US10478574B2 (en) 2006-01-19 2019-11-19 Optinose As Nasal administration
GB0602980D0 (en) 2006-02-14 2006-03-29 Optinose As Delivery device and method
WO2007093784A1 (en) 2006-02-14 2007-08-23 Optinose As Delivery device and method
GB0604319D0 (en) 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB0604444D0 (en) * 2006-03-06 2006-04-12 Optinose As Nasal devices
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
GB2437488A (en) 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
JP2008062974A (ja) * 2006-09-07 2008-03-21 Mitani Valve Co Ltd 内容物放出用容器ならびに、この内容物放出用容器を備えたポンプ式製品およびエアゾール式製品
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
GB0623731D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery device
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
WO2008122018A1 (en) 2007-04-02 2008-10-09 Abbott Respiratory Llc Breath actuated nasal pump
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
GB2448193A (en) * 2007-04-05 2008-10-08 Optinose As Nasal delivery device
US8342173B2 (en) 2007-07-19 2013-01-01 Silver Eagle Labs Inc. Nasal dilator with cushion layer and variable spring rate
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
ES2648196T3 (es) 2008-02-07 2017-12-29 The University Of Washington Dispositivo aerosol circunferencial
WO2009102976A2 (en) 2008-02-15 2009-08-20 Timothy Sean Immel Aerosol therapy device with high frequency delivery
US20110318345A1 (en) 2008-09-15 2011-12-29 Optinose As Nasal delivery
GB201015371D0 (en) 2010-09-14 2010-10-27 Optinose As Nasal delivery
GB201020638D0 (en) 2010-12-06 2011-01-19 Liconsa Laboratorios Sa Inhalator
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
RU112044U1 (ru) * 2011-08-25 2012-01-10 Наиль Минрахманович Нуртдинов Тренажер-ингалятор
MX358061B (es) 2012-02-24 2018-08-03 Optinose As Dispositivos de suministro nasal.
MX352029B (es) 2012-02-24 2017-11-07 Optinose As Dispositivos de suministro nasal.
US10179216B2 (en) 2012-02-24 2019-01-15 Optinose As Nasal delivery devices
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
EP4062939A1 (en) 2013-03-26 2022-09-28 Optinose AS Nasal administration
USD761951S1 (en) 2013-05-23 2016-07-19 Optinose As Nosepiece unit
USD725769S1 (en) 2013-05-23 2015-03-31 Optinose As Nasal delivery device
USD723156S1 (en) 2013-05-23 2015-02-24 Optinose As Nasal delivery device
CN107106792B (zh) 2014-11-19 2020-08-18 奥普蒂诺斯公司 经鼻给药
US20220296825A1 (en) 2018-10-04 2022-09-22 Optinose As Exhalation delivery system for and method of treating sinus disease

Also Published As

Publication number Publication date
ES2906984T3 (es) 2022-04-21
HK1244729A1 (zh) 2018-08-17
US20160331916A1 (en) 2016-11-17
CN106999684A (zh) 2017-08-01
BR112017010522B1 (pt) 2022-08-02
KR20170086599A (ko) 2017-07-26
DK3220989T3 (da) 2020-08-24
IL251936B (en) 2020-07-30
CA2966797A1 (en) 2016-05-26
WO2016079271A1 (en) 2016-05-26
EP3220988B1 (en) 2022-01-12
JP2017538478A (ja) 2017-12-28
DK3220988T3 (da) 2022-02-14
US20210275761A1 (en) 2021-09-09
US20230372647A1 (en) 2023-11-23
RU2017114950A (ru) 2018-12-19
AU2015348301A1 (en) 2017-05-25
US11707586B2 (en) 2023-07-25
EP3220989B1 (en) 2020-06-24
EP3733235B1 (en) 2023-06-14
MX2017006265A (es) 2017-08-14
RU2017114951A3 (es) 2019-04-16
MY188242A (en) 2021-11-24
ES2949052T3 (es) 2023-09-25
KR20170085121A (ko) 2017-07-21
ES2813442T3 (es) 2021-03-23
CA2966802A1 (en) 2016-05-26
JP6990583B2 (ja) 2022-01-12
SG11201703794TA (en) 2017-06-29
RU2714168C2 (ru) 2020-02-12
IL251936A0 (en) 2017-06-29
CA2966802C (en) 2022-11-15
AU2015348301B2 (en) 2020-09-03
CN107106792B (zh) 2020-08-18
BR112017010561A2 (pt) 2017-12-26
RU2017114951A (ru) 2018-12-19
BR112017010522A2 (pt) 2017-12-26
JP2017538477A (ja) 2017-12-28
JP6937690B2 (ja) 2021-09-22
CN111921046B (zh) 2022-07-22
CN106999684B (zh) 2021-03-09
EP3733235A1 (en) 2020-11-04
SG11201703792XA (en) 2017-06-29
IL251935A0 (en) 2017-06-29
US20160310683A1 (en) 2016-10-27
US20210322690A1 (en) 2021-10-21
HK1244728A1 (zh) 2018-08-17
EP3733235C0 (en) 2023-06-14
US10940277B2 (en) 2021-03-09
CN107106792A (zh) 2017-08-29
AU2015348297A1 (en) 2017-05-25
CN111921046A (zh) 2020-11-13
EP3220989A1 (en) 2017-09-27
CA2966797C (en) 2023-06-27
US11730904B2 (en) 2023-08-22
ZA201704149B (en) 2019-12-18
US11052204B2 (en) 2021-07-06
WO2016079267A1 (en) 2016-05-26
EP3220988A1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
MX2017006268A (es) Administracion intranasal.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MY170349A (en) Nasal delivery devices
MX2017005204A (es) Dispositivos y métodos de estimulación para tratar el ojo seco.
GB201115972D0 (en) Nasal delivery
MA40630A (fr) Dispositif d'administration d'un agent thérapeutique muni d'une canule et d'une aiguille pouvant avancer.
EP4252833A3 (en) Microstimulation sleep disordered breathing (sdb) therapy device
MX2016015179A (es) Una formulación líquida que comprende nicotina para administracion en aerosol.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
NZ630742A (en) A patient interface
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
NZ630741A (en) Patient interface for respiratory therapy
EA201491844A1 (ru) Распыляющие спрей эжекторные механизмы и устройства, выполненные с изоляцией и возможностью управляемого создания заряда на каплях, и нанесение малообъемных доз офтальмологических средств
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
TWD222134S (zh) 病患連接裝置
SA516370641B1 (ar) مركبات حلقية غير متجانسة وطرق لاستخدامها
TWD190432S (zh) 鼻管
MX2017003255A (es) Electrodo tipo cuff de nervios para neuromodulación en troncos nerviosos grandes de humano.
GB2540110A (en) Corneal inlay delivery devices and methods
PH12017501086A1 (en) Liquid discharge device and intermediate retaining body
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
EA201691132A1 (ru) Инъекционное средство и способ образования депо
MX2020003049A (es) Semaglutida en la terapia medica.
PH12017500538A1 (en) Inhalation device
SG10201807477PA (en) Real-time feedback system control technology platform with dynamically changing stimulations